Department of Hematology, Wuxi People Hospital Affiliated of Nanjing Medical University, Wuxi, Jiangsu, China.
Clin Lymphoma Myeloma Leuk. 2010 Oct;10(5):347-52. doi: 10.3816/CLML.2010.n.067.
It has been 40 years since the discovery of Fcγ receptors (FcγRs) and their function. FcγRs regulate a variety of immune responses, including phagocytosis, degranulation, antibody-dependent cellular cytotoxicity, transcriptional regulation of cytokines, chemokine expression, B-cell activation, and immune complex clearance. It is well known that FcγRs serve as a critical link between the humoral and cellular branches of the immune system and play an important role in many conditions, including infection, cancer, and autoimmune diseases. Recent studies suggest that FcγR polymorphisms influence efficacy and side effects of monoclonal antibody-based immunotherapy, which might provide a useful prognostic marker for treatment in the future. Rituximab has been proven effective in treating patients with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Some FcγR genotypes correlate with rituximab efficacy in patients with NHL but not in patients with CLL. In this review, FcγR function and the association between FcγR polymorphisms and rituximab efficacy in NHL and CLL are discussed.
自 Fcγ 受体（FcγRs）被发现及其功能被阐明以来，已经过去了 40 年。FcγRs 调节多种免疫反应，包括吞噬作用、脱颗粒、抗体依赖性细胞毒性、细胞因子转录调节、趋化因子表达、B 细胞激活和免疫复合物清除。众所周知，FcγRs 是免疫系统体液和细胞分支之间的关键环节，在感染、癌症和自身免疫性疾病等多种情况下发挥着重要作用。最近的研究表明，FcγR 多态性影响基于单克隆抗体的免疫治疗的疗效和副作用，这可能为未来的治疗提供有用的预后标志物。利妥昔单抗已被证明对治疗非霍奇金淋巴瘤（NHL）和慢性淋巴细胞白血病（CLL）患者有效。一些 FcγR 基因型与 NHL 患者的利妥昔单抗疗效相关，但与 CLL 患者无关。本文综述了 FcγR 的功能以及 FcγR 多态性与 NHL 和 CLL 中利妥昔单抗疗效之间的关系。
